Ascendis Pharma A/S filed updated Articles of Association effective 14 April 2026 detailing current share capital, warrant issuances, exercises, and ongoing Board authorizations for capital increases until 2030.
Key takeaways
Share capital is DKK 62,376,846 fully paid up, divided into DKK 1 shares.
Total of 13,548,940 warrants issued across various authorizations, with 8,627,838 exercised, annulled or lapsed as of 14 April 2026.
Board authorized to increase share capital by up to DKK 9,000,000 with pre-emptive rights until 29 May 2029.
Board authorized for DKK 3,825,000 capital increase without pre-emptive rights until 27 May 2030 via cash, kind or debt conversion.
Recent warrants issued under Article 4f in 2023-2025 totaling 125,307 with exercise prices from USD 110.19 to USD 145.63.
Authorization for convertible bonds up to DKK 9,000,000 share capital increase until 29 May 2027.